- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Emcure Pharmaceuticals has published its Annual Report for FY25 and announced its 44th Annual General Meeting (AGM) to be held via video conferencing. The company reported strong consolidated revenue growth of 18.6% to ₹7,896 Cr and a 34.1% increase in consolidated profit after tax to ₹707.5 Cr. Key highlights include successful stock exchange listing, a proposed ₹3 dividend per share, strategic acquisitions like Mantra Pharma, and expansion into new therapeutic areas. Shareholders will consider director re-appointments and approvals for executive remuneration, reflecting the company's growth trajectory and ongoing strategic initiatives.